 Ascendis Pharma AS ASND, a biopharmaceutical company that utilizes its innovative TransCon technologies to address unmet medical needs, today announced that the United States U.S. Food and Drug Administration FDA has granted Orphan Drug Designation ODD to TransCon hGH lonapegsomatropin, as 